U.S. markets open in 17 minutes
  • S&P Futures

    3,846.00
    +18.00 (+0.47%)
     
  • Dow Futures

    31,365.00
    -6.00 (-0.02%)
     
  • Nasdaq Futures

    12,963.50
    +131.75 (+1.03%)
     
  • Russell 2000 Futures

    2,206.40
    +6.40 (+0.29%)
     
  • Crude Oil

    62.48
    -1.05 (-1.65%)
     
  • Gold

    1,761.60
    -13.80 (-0.78%)
     
  • Silver

    26.93
    -0.75 (-2.71%)
     
  • EUR/USD

    1.2126
    -0.0061 (-0.50%)
     
  • 10-Yr Bond

    1.4670
    -0.0510 (-3.36%)
     
  • Vix

    27.74
    +6.40 (+29.99%)
     
  • GBP/USD

    1.3976
    -0.0037 (-0.26%)
     
  • USD/JPY

    106.3580
    +0.1280 (+0.12%)
     
  • BTC-USD

    46,197.92
    -5,620.88 (-10.85%)
     
  • CMC Crypto 200

    923.43
    -9.71 (-1.04%)
     
  • FTSE 100

    6,544.61
    -107.35 (-1.61%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

How Much Of AC Immune SA (NASDAQ:ACIU) Do Insiders Own?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of AC Immune SA (NASDAQ:ACIU) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.

AC Immune is a smaller company with a market capitalization of US$494m, so it may still be flying under the radar of many institutional investors. In the chart below, we can see that institutional investors have bought into the company. We can zoom in on the different ownership groups, to learn more about AC Immune.

See our latest analysis for AC Immune

NasdaqGM:ACIU Ownership Breakdown July 7th 2020
NasdaqGM:ACIU Ownership Breakdown July 7th 2020

What Does The Institutional Ownership Tell Us About AC Immune?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in AC Immune. This suggests some credibility amongst professional investors. But we can't rely on that fact alone, since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see AC Immune's historic earnings and revenue, below, but keep in mind there's always more to the story.

NasdaqGM:ACIU Earnings and Revenue Growth July 7th 2020
NasdaqGM:ACIU Earnings and Revenue Growth July 7th 2020

It would appear that 16% of AC Immune shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Our data shows that dievini Hopp BioTech holding GmbH & Co. KG is the largest shareholder with 25% of shares outstanding. In comparison, the second and third largest shareholders hold about 17% and 16% of the stock. Additionally, the company's CEO Andrea Pfeifer directly holds 3.6% of the total shares outstanding.

A more detailed study of the shareholder registry showed us that 3 of the top shareholders have a considerable amount of ownership in the company, via their 58% stake.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of AC Immune

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board; and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board, themselves.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

We can see that insiders own shares in AC Immune SA. As individuals, the insiders collectively own US$25m worth of the US$494m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public holds a 25% stake in ACIU. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

Private equity firms hold a 42% stake in ACIU. This suggests they can be influential in key policy decisions. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks, for example - AC Immune has 2 warning signs we think you should be aware of.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.